Imara

700 Technology Square, 3rd Floor
Cambridge
Massachusetts
02139
United States

Tel: 1-617-231-6021

Email: info@imaratx.com

Show jobs for this employer

About Imara

Imara Inc., is dedicated to developing novel therapeutics for people living with sickle cell disease and other hemoglobinopathies. Sickle cell disease is a rare, genetic blood disease that causes red blood cells to sickle and become damaged, activating immune cells and blocking blood flow in capillaries, injuring many organs and causing daily pain. Imara is developing IMR-687, a highly selective, potent small molecule inhibitor of phosphodiesterase-9 (PDE9i), to treat patients with sickle cell disease. Imara was launched following an 18-month scientific collaboration between orphan drug accelerator Cydan Development and H. Lundbeck A/S.
YEAR FOUNDED:
2016
LEADERSHIP:
Founder and CEO: James McArthur
CLINICAL TRIAL:
Please click here for clinical trial information.

19 articles with Imara